Sarbjit Singh Saini MD
Asthma & Allergic Conditions
Professor of Medicine, Johns Hopkins University School of Medicine Director, Allergy and Immunology Fellowship Program
Join to View Full Profile
5501 Hopkins Bayview CircleAllergy & Asthma Center, 2nd FloorBaltimore, MD 21224
Phone+1 410-550-2300
Fax+1 410-550-3256
Dr. Saini is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sarbjit Saini is an allergist/immunologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. He received his medical degree from The Ohio State University College of Medicine and has been in practice 26 years.
Education & Training
Johns Hopkins UniversityFellowship, Allergy and Immunology, 1994 - 1997
University of MichiganResidency, Internal Medicine, 1991 - 1994
Ohio State University College of MedicineClass of 1991
Certifications & Licensure
FL State Medical License 2020 - Present
MD State Medical License 1995 - 2025
MI State Medical License 1993 - 1997
American Board of Allergy and Immunology Allergy & Immunology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Effect of Anti-IgE in Chronic Urticaria Start of enrollment: 2004 Nov 01
- Omalizumab in the Treatment of Peanut Allergy Start of enrollment: 2009 Jul 01
- The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge Start of enrollment: 2009 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Remibrutinib in Chronic Spontaneous Urticaria.Martin Metz, Ana Giménez-Arnau, Michihiro Hide, Mark Lebwohl, Giselle Mosnaim
The New England Journal of Medicine. 2025-03-06 - Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe.Tomoko Hasunuma, Clive Grattan, Takashi Eto, Michio Yagi, Rie Yazawa
Immunotherapy. 2025-02-01 - 1 citationsCT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study.Sarbjit S Saini, Marcus Maurer, Yevgeniya Dytyatkovska, Ewa Springer, Maria Ratkova
Allergy. 2025-01-09
Other
- Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural historySaini S
http://www.uptodate.com/contents/chronic-urticaria-clinical-manifestations-diagnosis-pathogenesis-an
UpToDate, Wolters Kluwer Health - 2013-01-28
Press Mentions
Novel BTK Inhibitor for Chronic Hives Wins in Phase III TrialNovember 16th, 2023
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/sarbjit-saini
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
